Kostis J B, Davis D, Kluger J, Aogaichi K, Smith M
Division of Cardiovascular Diseases and Hypertension, UMDNJ-Robert Wood Johnson Medical School, New Brunswick 08903-0019.
J Cardiovasc Pharmacol. 1989 Jul;14(1):88-95. doi: 10.1097/00005344-198907000-00016.
To study the efficacy and safety of cifenline (cibenzoline), a new antiarrhythmic agent, we enrolled 46 patients with greater than 700 premature ventricular complexes (VPCs)/24 h in an ambulatory electrocardiography study. During an open-label titration phase, 25 patients showed greater than 75% VPC suppression while receiving 130 mg (15 patients) or 160 mg (10 patients) cifenline twice daily. During a double-blind placebo-controlled phase in 23 of these patients, cifenline was more effective than placebo in controlling VPCs (p less than 0.0001) and VPC pairs (p less than 0.025). A small (0.01 s) increase in QRS duration was observed (p less than 0.05) during cifenline treatment. Adverse experiences included gastrointestinal complaints and dizziness as well as two instances of hypotension and one instance of symptomatic ventricular tachycardia. Cifenline appears to be effective and well tolerated in the treatment of VPCs.
为研究新型抗心律失常药物西苯唑啉的疗效和安全性，我们选取了46例动态心电图显示24小时室性早搏（VPC）超过700次的患者进行研究。在开放标签滴定阶段，25例患者在每日两次服用130毫克（15例患者）或160毫克（10例患者）西苯唑啉时，室性早搏抑制率超过75%。在其中23例患者的双盲安慰剂对照阶段，西苯唑啉在控制室性早搏（p<0.0001）和室性早搏对（p<0.025）方面比安慰剂更有效。在西苯唑啉治疗期间，观察到QRS时限小幅增加（0.01秒）（p<0.05）。不良事件包括胃肠道不适、头晕，以及两例低血压和一例症状性室性心动过速。西苯唑啉在治疗室性早搏方面似乎有效且耐受性良好。
